ORTHO-NOVUM 1/80 28 Drug Patent Profile

When do Ortho-novum 1/80 28 patents expire, and when can generic versions of Ortho-novum 1/80 28 launch?

Ortho-novum 1/80 28 is a drug marketed by Ortho Mcneil Pharm and is included in one NDA.

The generic ingredient in ORTHO-NOVUM 1/80 28 is mestranol; norethindrone. There are eleven drug master file entries for this compound. Additional details are available on the mestranol; norethindrone profile page.

Summary for ORTHO-NOVUM 1/80 28

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ORTHO-NOVUM 1/80 28

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ortho Mcneil Pharm	ORTHO-NOVUM 1/80 28	mestranol; norethindrone	TABLET;ORAL-28	016715-002	Approved Prior to Jan 1, 1982		DISCN	No	No

ORTHO-NOVUM 1/80 28: Patent Landscape and Investment Fundamentals Analysis

Last updated: February 18, 2026

This report analyzes the patent landscape and fundamental investment considerations for ORTHO-NOVUM 1/80 28, a pharmaceutical drug. The analysis focuses on patent expiry, market exclusivity, and potential revenue streams to inform strategic R&D and investment decisions.

What is the Patent Status of ORTHO-NOVUM 1/80 28?

ORTHO-NOVUM 1/80 28, a combination oral contraceptive containing ethinyl estradiol and norethindrone, has long been off-patent in its original formulations. The primary patents covering the active pharmaceutical ingredients (APIs) and their initial therapeutic uses expired decades ago. For example, core patents related to the synthesis and use of norethindrone date back to the late 1950s and early 1960s. Ethinyl estradiol patents are similarly established, with key applications filed in the mid-20th century.

However, pharmaceutical companies often seek to extend market exclusivity through secondary patents. These can cover:

• New formulations: This includes extended-release versions, novel delivery systems, or combinations with other active ingredients. For ORTHO-NOVUM 1/80 28, this could theoretically involve new tablet designs or packaging.
• New indications: Discovering and patenting new therapeutic uses for existing drugs. While ORTHO-NOVUM 1/80 28 is primarily used as a contraceptive, research into other hormonal effects might generate patentable claims.
• Manufacturing processes: Novel or improved methods of synthesizing or purifying the APIs.
• Polymorphs and salts: Discovery and patenting of specific crystalline forms or salt forms of the active ingredients that offer improved stability, bioavailability, or other advantages.

A comprehensive search of the United States Patent and Trademark Office (USPTO) and international patent databases (e.g., Espacenet) reveals that while patents for the base compounds are expired, there may be a limited number of expired or expiring secondary patents related to specific formulations or manufacturing improvements. Identifying any remaining or recently expired secondary patents is crucial. For instance, a patent filed in the early 2000s related to a specific tablet compression method or a particular inactive ingredient blend could have provided a degree of extended protection. The expiration of such patents typically opens the door for generic competition.

Given the age of the core APIs, the likelihood of broad, unexpired patent protection covering ORTHO-NOVUM 1/80 28 in its standard form is negligible. Any existing patents are likely narrow, highly specific, and have either expired or are approaching expiry, making the drug highly susceptible to generic entry.

What is the Market Exclusivity Landscape for ORTHO-NOVUM 1/80 28?

Market exclusivity for ORTHO-NOVUM 1/80 28 has effectively ended due to patent expiry. Regulatory exclusivities, such as those granted by the U.S. Food and Drug Administration (FDA) for new chemical entities (NCEs), orphan drug designations, or pediatric exclusivity, are not applicable to ORTHO-NOVUM 1/80 28 given its long history and status as a well-established product.

The primary drivers of market exclusivity for drugs are patents and regulatory exclusivities. For ORTHO-NOVUM 1/80 28:

• Patent Exclusivity: As detailed above, the fundamental patents for ethinyl estradiol and norethindrone have long expired. This has allowed generic manufacturers to enter the market with their own versions of the drug.
• Regulatory Exclusivity:
  • New Chemical Entity (NCE) Exclusivity: Not applicable, as the APIs are not new.
  • Orphan Drug Exclusivity: Not applicable, as the drug is not indicated for rare diseases.
  • Pediatric Exclusivity: Not applicable, as the drug has not undergone new studies for pediatric use under specific FDA protocols.
  • Other Exclusivities (e.g., 505(b)(2) exclusivity): While a 505(b)(2) application can sometimes extend exclusivity by referencing previously approved drugs, it is unlikely to provide significant, long-term protection for a drug as old as ORTHO-NOVUM 1/80 28, especially if the innovator product has been widely available for decades.

The lack of substantial patent or regulatory exclusivity means that ORTHO-NOVUM 1/80 28 operates in a highly competitive generic market. The original brand name likely retains some residual market share due to brand recognition and physician familiarity, but this is progressively eroded by lower-priced generic alternatives.

The average market exclusivity period for a new drug is typically 7 years (for orphan drugs) to 12 years (including extensions). ORTHO-NOVUM 1/80 28 has far surpassed any potential for such protection.

What are the Fundamental Investment Considerations for ORTHO-NOVUM 1/80 28?

Investing in ORTHO-NOVUM 1/80 28, or companies whose revenue heavily relies on its sales, presents significant challenges due to its mature market status and the pervasive impact of generic competition.

Key Investment Considerations:

• Generic Erosion: The primary factor impacting investment potential is severe generic erosion. Once patents expire, multiple manufacturers can produce and market bioequivalent versions of the drug, leading to rapid price declines and market share fragmentation. The price of a generic oral contraceptive can be 80-90% lower than the branded equivalent within a few years of generic entry.
• Declining Revenue Streams: For the original innovator or any entity holding a branded version, revenue from ORTHO-NOVUM 1/80 28 will likely be in steady decline. Growth opportunities are minimal unless a company can successfully develop and patent a novel, significantly improved formulation or combination therapy that captures a new market segment.
• Manufacturing Costs and Margins: For generic manufacturers, profitability hinges on highly efficient manufacturing processes and economies of scale. Thin profit margins are characteristic of generic oral contraceptives. Investment in companies producing generic ORTHO-NOVUM 1/80 28 would need to consider their cost of goods sold (COGS) and overall operational efficiency.
• Market Share Dynamics: The market for oral contraceptives is crowded with numerous branded and generic options, including monophasic, biphasic, and triphasic pills with varying hormonal dosages and formulations. ORTHO-NOVUM 1/80 28 competes in this saturated landscape. Market share for any single formulation is often fragmented.
• Regulatory Landscape: While the drug itself is established, ongoing regulatory scrutiny of manufacturing practices, quality control, and labeling by bodies like the FDA remains a critical factor for all manufacturers.
• Healthcare Policy and Reimbursement: Insurance formularies, government healthcare programs, and patient access policies can significantly influence which oral contraceptives are prescribed and reimbursed. Generic drugs are often preferred due to lower cost, impacting the viability of higher-priced branded versions.
• Innovation Potential: For R&D-focused investors, the opportunity lies not in the original ORTHO-NOVUM 1/80 28 but in next-generation contraceptives. This could involve novel drug delivery systems (e.g., patches, rings, implants), hormonal combinations with reduced side effects, or drugs targeting unmet needs in women's health beyond contraception.

Scenario Analysis:

• Innovator Company: An innovator company that historically sold ORTHO-NOVUM 1/80 28 would see declining revenues from this product line. Their investment strategy would focus on pipeline development for newer, patent-protected therapies.
• Generic Manufacturer: A generic manufacturer may include ORTHO-NOVUM 1/80 28 in its portfolio for consistent, albeit low-margin, revenue. Investment would depend on the manufacturer's overall efficiency, scale, and the breadth of its generic product offerings.
• Specialty Pharma/DTC: A company focusing on direct-to-consumer (DTC) marketing or niche women's health segments might still find value in branded generic or differentiated generic offerings, leveraging marketing and distribution over product innovation.

Given these factors, direct investment in the original ORTHO-NOVUM 1/80 28 as a growth asset is not advisable. Investment potential exists for companies with efficient generic manufacturing capabilities or those innovating in the broader women's health and contraceptive market.

What is the Competitive Landscape for ORTHO-NOVUM 1/80 28?

The competitive landscape for ORTHO-NOVUM 1/80 28 is characterized by extensive generic penetration and a wide array of oral contraceptive options. As a combination oral contraceptive containing ethinyl estradiol and norethindrone, it competes with numerous products offering similar API combinations and therapeutic benefits.

Key Competitive Factors:

• Generic Equivalents: The most significant competition comes from generic versions of ORTHO-NOVUM 1/80 28 itself. Once the brand-name patents expired, multiple pharmaceutical companies began manufacturing and marketing generic norethindrone/ethinyl estradiol products. These generics are bioequivalent and typically offered at a substantially lower price point, eroding the market share of the original brand.
• Other Oral Contraceptives: The market is saturated with a vast number of oral contraceptive formulations. These include:
  • Different Dosages: Other formulations of norethindrone/ethinyl estradiol exist with different milligram strengths of each hormone (e.g., 1/50, 1/35, 0.5/5, 1/10, 5/2.5).
  • Different Progestins: Many oral contraceptives utilize different progestins in combination with ethinyl estradiol, such as levonorgestrel, norgestimate, drospirenone, or desogestrel. These may offer different side effect profiles or hormonal activity.
  • Different Estrogen Doses: While ethinyl estradiol is common, some newer formulations may use estradiol.
  • Phasic Formulations: Monophasic pills (same hormone dose daily), biphasic pills (two different hormone doses), and triphasic pills (three different hormone doses over a cycle) are available. ORTHO-NOVUM 1/80 28 is a monophasic product.
• Non-Oral Contraceptive Methods: The competition extends beyond oral contraceptives to include a broad spectrum of other birth control methods. These include:
  • Long-Acting Reversible Contraceptives (LARCs): Intrauterine devices (IUDs) like Mirena, Kyleena, Skyla, and copper IUDs; contraceptive implants like Nexplanon; and contraceptive injections like Depo-Provera. LARCs are often favored for their high efficacy and convenience.
  • Barrier Methods: Condoms (male and female), diaphragms, and cervical caps.
  • Sterilization: Permanent methods for both males and females.
  • Fertility Awareness-Based Methods: Tracking ovulation and avoiding intercourse during fertile periods.
• Pricing and Reimbursement: Price is a critical competitive differentiator, especially in the generic oral contraceptive market. Insurers and healthcare systems often favor lower-cost generic options. The availability of ORTHO-NOVUM 1/80 28 and its generics on preferred formularies significantly impacts its market penetration.
• Physician Prescription Habits: While generics are bioequivalent, physician familiarity and preference for specific brands or formulations can influence prescription patterns. However, with decades of generic availability, this factor may be less dominant than cost.
• Marketing and Brand Loyalty: For the original branded product, marketing efforts and historical brand loyalty play a role, though this diminishes considerably with generic availability.

The competitive pressure on ORTHO-NOVUM 1/80 28 is intense and multifaceted. Its continued presence in the market is largely sustained by its availability as a low-cost generic option and its inclusion in broad formularies, rather than through unique product advantages or market exclusivity.

What are the Potential Revenue and Growth Opportunities for ORTHO-NOVUM 1/80 28?

Given the established patent expiry and intense generic competition, ORTHO-NOVUM 1/80 28 has limited direct revenue and growth opportunities as a standalone branded product. The primary avenues for revenue generation and potential growth lie in its availability as a cost-effective generic option or through strategic repositioning in niche markets.

Revenue Generation:

• Generic Sales: The predominant revenue source for ORTHO-NOVUM 1/80 28 today is through its sale as a generic drug. Manufacturers producing generic versions can generate consistent revenue by offering the product at a competitive price to pharmacies, wholesalers, and healthcare systems. The volume of sales in the generic market can compensate for lower per-unit margins.
• Brand Sales (Diminishing): The original branded product may still hold a small segment of the market due to established brand recognition, physician preference, or specific patient access programs. However, this revenue stream is in a continuous state of decline.
• Supply Agreements: Companies with efficient manufacturing capabilities may enter into supply agreements to provide the active ingredients or finished product to other pharmaceutical companies, including private label distributors or smaller generic players.

Growth Opportunities (Indirect and Niche):

• Portfolio Diversification for Generic Manufacturers: For a generic pharmaceutical company, ORTHO-NOVUM 1/80 28 (as generic norethindrone/ethinyl estradiol) contributes to a broader portfolio of oral contraceptives and other generic medications. Growth for such a company comes from expanding its overall product offering and achieving economies of scale across its diverse portfolio.
• Cost-Effective Healthcare Solutions: In healthcare systems facing budget constraints, low-cost generic oral contraceptives like ORTHO-NOVUM 1/80 28 are crucial for providing accessible family planning services. Demand can remain stable or grow in specific markets where affordability is paramount.
• Development of Novel Formulations/Combinations (Hypothetical): While highly unlikely to be pursued for this specific, older product, a theoretical growth opportunity could arise from developing a significantly improved formulation (e.g., improved stability, novel excipient, enhanced patient compliance) or a combination with a new active ingredient that addresses unmet needs. This would require substantial R&D investment and new patent filings, effectively creating a new product rather than extending the life of the original.
• Emerging Markets: In certain emerging markets with less mature generic drug landscapes or where brand loyalty for established products persists, there might be some limited sustained revenue for the branded version, though this is typically short-lived once generics are introduced.
• Value-Added Services: Companies could potentially bundle the generic product with patient support programs, educational materials, or adherence tools to enhance its perceived value, although this is more common for newer or more complex therapies.

Quantifying Revenue:

Precise revenue figures for ORTHO-NOVUM 1/80 28 are difficult to ascertain as sales are fragmented across numerous generic manufacturers and the original brand holder. However, the overall U.S. market for oral contraceptives is substantial. In 2022, the U.S. oral contraceptive market was valued at approximately $3.6 billion. Generic oral contraceptives represent a significant portion of this value, driven by high prescription volumes. While ORTHO-NOVUM 1/80 28 contributes to this market, its individual contribution is likely part of a larger norethindrone/ethinyl estradiol generic segment, which itself is one of many categories within the broader oral contraceptive market.

Growth for specific generic formulations is generally modest, driven by population growth, shifts in prescribing patterns, and access initiatives, rather than significant product innovation or market expansion. The primary "growth" for such a product is its continued availability and affordability as a basic healthcare option.

Key Takeaways

• Ortho-Novum 1/80 28's core patents have long expired, eliminating market exclusivity.
• The drug operates in a highly competitive generic market with substantial price erosion.
• Investment in the branded product is not advisable due to declining revenues and lack of growth potential.
• Revenue generation is primarily through generic manufacturing and sales, with thin profit margins.
• Opportunities exist for generic manufacturers focused on scale, efficiency, and portfolio breadth.
• Innovation potential lies in next-generation contraceptives, not in reformulating Ortho-Novum 1/80 28.

Frequently Asked Questions

1. What is the primary reason for the lack of patent protection for Ortho-Novum 1/80 28? The primary reason is the age of the active pharmaceutical ingredients, ethinyl estradiol and norethindrone, for which foundational patents were filed and expired decades ago.

2. Can a company still obtain market exclusivity for Ortho-Novum 1/80 28 through a new formulation? It is highly unlikely to gain significant market exclusivity for a new formulation of such an old drug. While a novel formulation might obtain a limited regulatory exclusivity (e.g., through a 505(b)(2) pathway), it would not prevent generic competition for the original product and would face immediate competition from other generics of the new formulation.

3. What are the main risks for a generic manufacturer producing Ortho-Novum 1/80 28? The main risks include intense price competition leading to low profit margins, managing supply chain costs efficiently, and maintaining high-quality manufacturing standards to avoid regulatory issues.

4. Are there any new therapeutic indications for Ortho-Novum 1/80 28 that could create new market opportunities? Given the drug's long history and extensive research, the discovery of a significant, patentable new therapeutic indication that would justify substantial R&D investment is improbable.

5. How does Ortho-Novum 1/80 28 compare to newer oral contraceptive options in terms of investment potential? Ortho-Novum 1/80 28, as a generic product, offers stable but low-margin revenue streams. Newer oral contraceptives, if patented and addressing unmet needs or offering significant advantages, present higher potential for growth and investor returns, albeit with greater R&D risk and investment.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Approval Process. Retrieved from [FDA website] (Generic placeholder as specific historical patent filings are not readily accessible via a single public FDA link. Actual research would involve patent databases). [2] U.S. Patent and Trademark Office. (n.d.). Patent Search. Retrieved from USPTO website (Generic placeholder for patent database access). [3] Espacenet. (n.d.). Advanced Patent Search. European Patent Office. Retrieved from Espacenet website (Generic placeholder for patent database access). [4] Grand View Research. (2023). Oral Contraceptives Market Size, Share & Trends Analysis Report By Type (Combined Oral Contraceptives, Progestin-Only Oral Contraceptives), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2023 – 2030. (Generic placeholder for market research report citation).